Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors |
| |
Authors: | Hayakawa Masahiko Kaizawa Hiroyuki Moritomo Hiroyuki Koizumi Tomonobu Ohishi Takahide Yamano Mayumi Okada Minoru Ohta Mitsuaki Tsukamoto Shin-ichi Raynaud Florence I Workman Paul Waterfield Michael D Parker Peter |
| |
Institution: | Drug Discovery Research, Astellas Pharma Inc., 5-2-3 Tokodai, Tsukuba, Ibaraki 300-2698, Japan. masahiko.hayakawa@jp.astellas.com |
| |
Abstract: | 4-Morpholin-4-ylpyrido3',2':4,5]thieno3,2-d]pyrimidine 2a was discovered in our chemical library as a novel p110alpha inhibitor with an IC(50) of 1.4 microM. By structural modification of 2a, the 2-aryl-4-morpholinopyrido3',2':4,5]furo3,2-d]pyrimidine derivative 10e was discovered as a p110alpha inhibitor with approximately 400-fold greater potency than 2a. Evaluation of isoform selectivity showed that 10e is a potent inhibitor of p110beta. Furthermore, 10e showed anti-proliferative activity in various cell lines, including multi-drug resistant MCF7/ADR-res cells, and was effective against HeLa human cervical tumor xenografts in nude mice. |
| |
Keywords: | |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|